Evome Medical Technologies Inc.
LNDZF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.70% | -13.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.70% | -13.98% | |||
| Cost of Revenue | -10.41% | -12.63% | |||
| Gross Profit | 7.75% | -16.77% | |||
| SG&A Expenses | -12.94% | -32.87% | |||
| Depreciation & Amortization | -0.77% | -20.72% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.54% | -20.73% | |||
| Operating Income | 61.86% | 53.07% | |||
| Income Before Tax | 49.25% | 47.77% | |||
| Income Tax Expenses | -100.00% | -- | |||
| Earnings from Continuing Operations | 49.51% | 47.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.51% | 47.50% | |||
| EBIT | 61.86% | 53.07% | |||
| EBITDA | 86.48% | 58.75% | |||
| EPS Basic | 49.73% | 50.41% | |||
| Normalized Basic EPS | 34.09% | 49.13% | |||
| EPS Diluted | 49.73% | 50.41% | |||
| Normalized Diluted EPS | 34.09% | 49.13% | |||
| Average Basic Shares Outstanding | 0.00% | 5.94% | |||
| Average Diluted Shares Outstanding | 0.00% | 5.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||